Climb Bio Q3 EPS $(0.19) Misses $(0.14) Estimate

Climb Bio (NASDAQ: CLYM) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.14) by 31.94 percent. This is a 46.15 percent decrease over losses of $(0.13) per share from the same period last year.